• 10/7/2004
  • Toronto, Ontario
  • Press release
  • Canada News Wire (cnw.ca)

Viventia Biotech Inc. a leading biopharmaceutical company focused on the discovery and development of a new generation of targeted anti-cancer drugs, announced today that Dr. Nick Glover, President and CEO of Viventia Biotech has been invited to make corporate presentations at three major biotechnology conferences. Dr. Glover will present before an international audience of investors, biotech professionals, journalists and representatives from large pharmaceutical companies in both North America and Europe.

Presentations will be made at BioContact Biopharmaceutical Partnering Symposium being held in Quebec City on October 6th – 8th, 2004. The Rodman & Renshaw Techvest Healthcare Conference in New York, October 26th – 28th, 2004 and BIO Europe 2004, the largest and most successful partnering forum in Europe being held November 8th – 10th, 2004 in Cologne, Germany.

Dr. Glover said, “Participation in these conferences allows Viventia the opportunity to present to an international audience the progress we have made in our mission, to discover and develop a new generation of monoclonal antibody products to offer safer, more beneficial therapies for cancer patients.” Viventia’s first Armed Antibodies(TM) product, Proxinium(TM), continues to rapidly move through clinical development in our first indication, the treatment of advanced, recurrent head and neck cancer. We have also recently initiated clinical development for Proxinium in a second indication, advanced bladder cancer.

Viventia Biotech Inc. is a biopharmaceutical company advancing a new generation of monoclonal antibody therapeutics designed to offer safer, more beneficial therapies for cancer patients. Viventia’s fully integrated technology platform is based upon the isolation of human monoclonal antibodies from cancer patients, and the development of those proteins, as Armed Antibodies(TM) to deliver cancer-killing payloads directly to cancer cells.

Viventia’s lead product candidate, Proxinium(TM), is in clinical development for the treatment of head and neck cancer and bladder cancer, and several other product candidates are in pre-clinical development.